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428Objective: The objective of this study was to determine whether a composite outcome, derived of objective
signs of inadequate cardiac output, would be associated with other important measures of outcomes and there-
fore be an appropriate end point for clinical trials in neonatal cardiac surgery.
Methods: Neonates (n ¼ 76) undergoing cardiac operations requiring cardiopulmonary bypass were prospec-
tively enrolled. Patients were defined to have met the composite outcome if they had any of the following events
before hospital discharge: death, the use of mechanical circulatory support, cardiac arrest requiring chest com-
pressions, hepatic injury (2 times the upper limit of normal for aspartate aminotransferase or alanine aminotrans-
ferase), renal injury (creatinine>1.5 mg/dL), or lactic acidosis (an increasing lactate>5 mmol/L in the
postoperative period). Associations between the composite outcome and the duration of mechanical ventilation,
intensive care unit stay, hospital stay, and total hospital charges were determined.
Results: The median age at the time of surgery was 7 days, and the median weight was 3.2 kg. The composite
outcomewasmet in 39% of patients (30/76). Patients whomet the composite outcome compared with thosewho
did not had a longer duration of mechanical ventilation (4.9 vs 2.9 days, P<.01), intensive care unit stay (8.8 vs
5.7 days, P<.01), hospital stay (23 vs 12 days, P<.01), and increased hospital charges ($258,000 vs $170,000,
P<.01). In linear regression analysis, controlling for surgical complexity, these differences remained significant
(R2 ¼ 0.29-0.42, P<.01).
Conclusions: The composite outcome is highly associated with important early operative outcomes and may
serve as a useful end point for future clinical research in neonates undergoing cardiac operations. (J Thorac Car-
diovasc Surg 2014;147:428-33)Advancements in surgical techniques and refinements
in perioperative management have led to significant im-
provements in survival after neonatal cardiac surgery, yet
significant morbidity persists.1-3 Accordingly, research
has shifted from not only improving survival but also
reducing morbidity.4 However, research in pediatric heart
disease is confronted by barriers, including small numbers
of subjects with a particular congenital heart defect at any
one center, differences in treatment approaches resulting
in a lack of therapeutic equipoise, and lack of validated out-
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The Journal of Thoracic and Cardiovascular Surgthe National Heart, Lung, and Blood Institute–funded Pedi-
atric Heart Network, and registries have been developed to
improve sample size and facilitate scientific investigation.5
However, validation of outcomes remains relatively unex-
plored. In congenital cardiac surgery, commonly used
outcomes include mortality, duration of mechanical ventila-
tion, intensive care unit (ICU) stay, and hospital stay.6,7 In
the neonatal population, these outcomes often can be
problematic because mortality is infrequent, and the other
outcomes often have a wide range or large standard
deviation resulting in inadequately powered studies or the
need for a large sample size. Many investigators have
used surrogate outcome measures, such as low cardiac
output syndrome, inotropic score, and vasoactive
inotropic score.6-8 Despite the intuitive nature of these
outcomes, a recent report demonstrated that low cardiac
output syndrome had a poor association and vasoactive
inotropic score had weak correlations with other clinically
important outcomes in neonates undergoing cardiac
operations.9 This highlights the need for further investiga-
tion into the validation of superior surrogate outcome mea-
sures in neonatal cardiac surgery.
An ideal early outcome measure would be easily mea-
sured, reproducible, and, most important, independently
correlated with other measures of short- and long-term out-
comes. Composite outcomes, which combine several com-
ponents into a single measure, have gained popularity in theery c January 2014
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ALT ¼ alanine aminotransferase
AST ¼ aspartate aminotransferase
CI ¼ confidence interval
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CPR ¼ cardiopulmonary resuscitation
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Butts et al Congenital Heart Diseasescientific community.10 The advantages supporting the use
of a composite outcome are that it increases statistical effi-
ciency because of higher event rates, which reduces sample
size requirement, cost, and time, and that it allows investi-
gators to avoid an arbitrary choice between several impor-
tant outcomes.11 These advantages have resulted in the
widespread use of composite outcomes in clinical trials, in-
cluding pediatric heart disease.12-14 The objective of this
study was to use a standardized composite outcome for
neonatal cardiac surgery in a well-characterized cohort
and correlate this composite outcome with other important
early postoperative outcomes.C
H
DMATERIALS AND METHODS
The study is a secondary analysis of a prospective randomized con-
trolled trial comparing preoperative glucocorticoid therapy in 76 neonates
(ClinicalTrials.gov Identifier NCT00934843).15 The study was approved
by the Medical University of South Carolina’s Institutional Review Board,
and informed written consent was obtained from the parent or legal guard-
ian of all participants.
Composite Outcome
The individual components of the composite outcome were composed
of clinical and laboratory signs of inadequate tissue oxygen delivery or cir-
culatory collapse. Six components were chosen because each represents
important early clinical outcomes, often resulting from low cardiac output,
and have been associated with poor outcomes in other studies.16-21 The
components include death, circulatory collapse requiring chest
compressions (cardiopulmonary resuscitation [CPR]), mechanical
circulatory support (extracorporeal membrane oxygenation [ECMO]),
hepatic insufficiency, renal insufficiency, and lactic acidosis. Hepatic
injury was defined as aspartate aminotransferase (AST) or alanine
aminotransferase (ALT) greater than 2 times the upper limit of normal
(normal range, AST 8-40 IU/L; hepatic injury, AST>80 IU/L; normal
range, ALT 7-40 IU/L; hepatic injury, ALT>80 IU/L). Elevated AST
within the first 24 postoperative hours was not considered hepatic
insufficiency because AST elevation was likely a result of hemolysis
related to cardiopulmonary bypass (CPB).22 Renal injury was defined by
an increase in creatinine during admission greater than 2 times the upper
limit of normal (normal range, 0.3-0.7; renal injury,>1.5 mg/dL). Lactic
acidosis was defined as an increasing arterial lactate concentration that
reached more than 5 mmol/dL postoperatively.16,23 Patients who
experienced any of the 6 components after cardiac surgery and before
hospital discharge were considered to have met the composite outcome.The Journal of Thoracic and CaLiver function panels were ordered as part of the study protocol on ar-
rival to the ICU and 36 hours after arrival. Additional liver function tests
were obtained as clinically indicated and analyzed for the composite out-
come. Serum creatinine was measured on arrival to the ICU from the oper-
ating room and then daily for a minimum of 2 days. It was common practice
during the study period to have creatinine levels checked daily while in the
ICU if arterial or central venous access was present; however, this practice
was not required by the study protocol. Lactate levels were obtained via ar-
terial catheters and obtained on arrival to the ICU and at 1 hour, 2 hours,
4 hours, 8 hours, 12 hours, and 24 hours postoperatively at a minimum
and more often as clinically indicated.
Study Population
All inpatient neonates (aged 30 days) scheduled to undergo cardiac
surgery involving CPB from July 2007 to July 2009 were eligible for this
study. Exclusion criteria included prematurity (defined as 36 weeks ges-
tational age at the time of surgery), previous treatment with or contraindi-
cation to steroid therapy, or preoperative use of mechanical circulatory
support or active resuscitation at the time of proposed randomization. Pa-
tients were randomly assigned to preoperative placebo and intraoperative
methylprednisolone (1 dose) or preoperative and intraoperative methyl-
prednisolone (2 doses). Details on the study population have been
reported.15
Data Analysis
The characteristics of the patients who met the composite outcome were
compared with those who did not with respect to surgical complexity by the
Risk Adjustment for Congenital Heart Surgery 1 (RACHS-1) classifica-
tion,24 age at surgery, weight at surgery, length of CPB, use of aprotinin, or
delayed sternal closure. Continuous datawere compared using theWilcoxon
rank-sum test; categoric datawere analyzedwith the chi-square test. Patients
whomet the composite outcomewere compared with thosewho did not with
respect to duration of postoperative mechanical ventilation, ICU stay, hospi-
tal stay, and hospital charges using the Wilcoxon rank-sum test.
To explore the associations between meeting more than 1 criteria or
meeting the more clinically significant criteria and outcomes, patients
were further separated into 3 groups based on the number of composite out-
come criteria met: none, only 1, andmore than 1. Patients were further clas-
sified as meeting 1 of the clinical criteria (CPR, ECMO, death), laboratory
criteria only (hepatic or renal injury, lactic acidosis), or no criteria. Com-
parisons were made between groups using the Kruskal–Wallis test for non-
parametric data. Because patients who die in the hospital often have more
extensive resource use, sensitivity analyses were performed to determine
whether findings changed significantly when those patients (n ¼ 2) were
excluded.
To perform linear regression analysis, postoperative outcomes were log-
transformed to create parametric distribution. Surgical complexity was
controlled in the regressions analysis by dichotomizing patients with
a RACHS-1 class of 5 or 6 and patients with a RACHS-1 class of 2 to 4.
An alpha level less than 0.05 was considered statistically significant.RESULTS
All 76 patients had complete records for review and were
included in the analysis. Patient demographics, cardiac di-
agnoses, surgical procedures performed, and intraoperative
parameters have been described.15 Median gestational age
was 39 weeks (interquartile range [IQR], 38-39.3). Median
weight at surgery was 3.2 kg (IQR, 2.9-3.5). Diagnostic
classification based on RACHS-1 class is shown in Table 1.
Of the 76 patients, 30 (39%) met the composite outcome.
There were 2 deaths before hospital discharge, resulting inrdiovascular Surgery c Volume 147, Number 1 429
TABLE 1. Diagnostic classification
RACHS-1 category N ¼ 76
2 6 (8%)
3 25 (33%)
4 25 (33%)
5 1 (1%)
6 19 (25%)
Corrective surgery 43 (57%)
RACHS-1, Risk-Adjusted Classification for Congenital Heart Surgery.
TABLE 3. Composite outcome and postoperative outcomes
Composite outcome
P valueYes (n ¼ 30) No (n ¼ 46)
Hospital stay (d) 23 (16-39) 12 (9-22) <.01
ICU stay (d) 8.8 (6.3-19) 5.7 (4.1-7) <.01
Mechanical ventilation (d) 4.9 (3.8-12.8) 2.9 (1.9-3.9) <.01
Hospital charges ($1000) 258 (188-403) 170 (137-211) <.01
Values displayed are medians (IQR). ICU, Intensive care unit.
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in 4 patients (for an inability to wean from CPB in 2 and
for low cardiac output in 2); all survived. Cardiac arrest re-
quiring chest compressions occurred in 3 patients, and all
were successfully resuscitated without the use of mechani-
cal support. A serum lactate that increased in the postoper-
ative period and that was greater than 5 mmol/L was present
in 14 patients. Hepatic injury occurred in 17 patients, and 4
patients had renal injury. More than 1 criterion for the com-
posite outcome was present in 10 patients.
Preoperative and intraoperative characteristics of those
who met the composite outcome compared with those
who did not are shown in Table 2. The group that met the
composite outcome had a higher RACHS-1 categorization
than the group that did not meet the composite outcome.
The groups were otherwise similar with respect to age
and weight at time of surgery, CPB time, use of aprotinin,
corrective versus palliative surgery, and use of delayed ster-
nal closure. Between steroid treatment groups, there were
no differences in meeting the composite outcome (49% 1
dose vs 51% 2 doses, P ¼ .8).
Patients who met the composite outcome had longer me-
dian hospital stay by 11 days, ICU stay by 3.1 days, me-
chanical ventilation by 2 days, and higher median hospital
charges by $88,000 compared with those who did not
meet the composite outcome (Table 3). Linear regression
analysis showed that after controlling for RACHS-1 classi-
fication, patients who met the composite outcome had an
83% longer hospital stay (95% confidence interval [CI],
42-137; R2 ¼ 0.42; P<.01), 88% longer ICU stay (95%TABLE 2. Patient characteristics and composite outcome
Composite outcome
P valueYes (n ¼ 30) No (n ¼ 46)
RACHS-1 class* 4 (4-6) 3 (3-4) .01
Age (d)* 7 (5-12) 7 (6-8) .95
Weight at surgery (kg)* 3.3 (2.8-3.6) 3.2 (2.9-3.5) .89
Delayed sternal closure, n (%) 19 (63%) 19 (41%) .06
CPB (min)* 162 (123-215) 155 (128-171) .28
Aprotinin use, n (%) 17 (57%) 17 (37%) .15
Corrective surgery, n (%) 16 (53%) 27 (59%) .82
RACHS-1, Risk-Adjusted Classification for Congenital Heart Surgery; CPB, cardio-
pulmonary bypass. *Continuous data expressed in median (IQR);Wilcoxon rank-sum
test performed.
430 The Journal of Thoracic and Cardiovascular SurgCI, 42-150; R2 ¼ 0.34; P<.01), 105% longer time on me-
chanical ventilation (95% CI, 42-197; R2 ¼ 0.29; P<.01),
and 52% higher total hospital charges (95% CI, 25-84;
R2 ¼ 0.33; P<.01).
Patients who met more than 1 criteria for the composite
outcome had longer median hospital stay by 20.5 days,
ICU stay by 11.6 days, mechanical ventilation by 7.8 days,
and higher median hospital charges by $193,000, compared
with those who met 1 criteria (Table 4). Patients who met 1
criteria had longer hospital stay, ICU stay, and mechanical
ventilation, and higher hospital charges compared with those
who met no criteria (Table 4 and Figure 1).
Patients who met 1 of the clinical criteria of death,
ECMO, or CPR had longer median hospital stay, ICU
stay, and mechanical ventilation, as well as higher medial
hospital charges, compared with those who met only labo-
ratory criteria (Table 5 and Figure 2). These differences
persisted when comparing patients who met the laboratory
criteria only with those who met no criteria (Table 5
and Figure 2). After excluding the 2 patients who died, all
associations shown in Tables 3, 4, and 5 remained
relatively unchanged and statistically significant (P<.01).DISCUSSION
The results of this study demonstrate that the composite
outcome is both reasonably prevalent and highly associated
with important early operative outcomes and thus may serve
as a useful end point for future clinical research in neonates
undergoing cardiac operations with CPB. The components
of the composite outcome were selected on the basis ofTABLE 4. Number of composite outcome criteria met and
postoperative outcomes
Composite outcome
P
value
Yes No
>1 (n ¼ 10) 1 (n ¼ 20) (n ¼ 46)
Hospital stay (d) 41.5 (24.0-60.0) 21.0 (16.5-36.0) 12.0 (9.0-22.0) <.01
ICU stay (d) 19.4 (10.8-36.0) 7.8 (6.1-10.3) 5.7 (4.1-7.0) <.01
Mechanical
ventilation (d)
12.4 (7.0-28.0) 4.6 (3.4-5.4) 2.9 (1.9-3.9) <.01
Hospital charges
($1000)
418 (267-506) 225 (184-262) 170 (137-211) <.01
Values displayed are medians (IQR),>1 ¼ patients who met 2 composite outcome
criteria, 1¼ patients who met 1 composite outcome criteria. ICU, Intensive care unit.
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FIGURE 1. Composite outcome and postoperative outcomes. Box-whisper plot of postoperative outcomes and composite outcome. Box represents IQR.
Dark bar represents median.Whiskers extend to range of outcome up to 1.53 the IQR.Circles represent outliers beyond 1.53 the IQR. 0¼ patients whomet
no composite outcome, 1 ¼ patients who met only 1 composite outcome criteria,>1 ¼ patients who met 2 composite outcome criteria. There is a statis-
tically significant increase in median hospital stay, median ICU stay, median mechanical ventilation, and median hospital charges between each category
(P<.01, Table 4). ICU, Intensive care unit; IQR, interquartile range.
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term outcomes after congenital cardiac surgery, and as such
represent clinically significant outcomes.16,18-21
The use of a composite outcome for end points in clinical
research is done frequently in cardiovascular research and
multiple other fields of medicine.10,25,26 Composite
outcomes have the advantage of increasing the event rate,
which increases the power of a study population, as long
as the composite outcome event rate is closer to 50%TABLE 5. Clinical or laboratory criteria of composite outcome met
and postoperative outcomes
Composite outcome
P
value
Yes No
Clinical (n ¼ 9)
Laboratory
only (n ¼ 21) (n ¼ 46)
Hospital stay (d) 36.0 (22.0-44.0) 21.0 (17.0-39.0) 12.0 (9.0-22.0) <.01
ICU stay (d) 15.5 (7.7-20.9) 8.1 (6.2-12.0) 5.7 (4.1-7.0) <.01
Mechanical
ventilation (d)
8.6 (5.8-19.0) 4.7 (3.8-6.9) 2.9 (1.9-3.9) <.01
Hospital charges
($1000)
403 (208-506) 245 (194-362) 170 (137-211) <.01
Values displayed are median (IQR). Clinical ¼ patients who had CPR or ECMO, or
died. Laboratory only¼ patients who had hepatic injury, renal injury, or lactic acido-
sis. ICU, Intensive care unit.
The Journal of Thoracic and Cathan any of the individual component event rates. The
studied composite outcome had an event rate of 39%,
which is closer to 50% than the most common individual
component, hepatic injury with a 22% event rate. Thus,
the use of this composite outcome will increase the power
of a study. The reduction in study population has the
advantages of reduced costs, ability to perform
investigations in a timely manner, and avoidance of an
arbitrary choice between several outcomes.
Despite the advantages of composite outcomes, their use
can be misleading. This may be particularly relevant when
the components of the composite outcome vary in clinical
importance. Studies demonstrate that the treatment effect
is often biggest for the less important components and
smallest for the most important component.11 This is con-
sistent with the present study in which the lower morbidity
components of the composite outcome (hepatic and renal
insufficiency and lactic acidosis) occurred more often
than the more significant components of death, CPR, or me-
chanical circulatory support. To help overcome this bias
toward less important components, a recent report sug-
gested that weighted composite indexes are superior mea-
sure end points in clinical trials.10 The results of our study
indicate that the clinical outcomes of death, ECMO, or
CPR should be weighted more than the laboratoryrdiovascular Surgery c Volume 147, Number 1 431
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FIGURE 2. Clinical or laboratory criteria of composite outcome met and postoperative outcomes. Box-whisper plot of postoperative outcomes and
whether clinical criteria, laboratory criteria only, or no composite outcome criteria were met. Box represents IQR. Dark bar represents median. Whiskers
extend to range of outcome up to 1.53 the IQR.Circles represent outliers beyond 1.53 the IQR. None¼ patients whomet no composite outcome, laboratory
only¼ patients whomet only laboratory composite outcome criteria, clinical¼ patients whomet any of the clinical composite outcome criteria (CPR, death,
ECMO). There is a statistically significant increase in median hospital stay, ICU stay, duration of mechanical ventilation, and hospital charges between each
category (P<.01, Table 5). ICU, Intensive care unit; IQR, interquartile range; CPR, cardiopulmonary resuscitation; ECMO, extracorporeal membrane ox-
ygenation.
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to determine the individual weight that should be applied to
each component of the composite outcome.Study Limitations
The components of the composite outcome and cutoffs
for liver injury, renal injury, and lactic acidosis were based
on previous reports, and each component was given equal
weight. The best methods to define hepatic injury, renal in-
jury, elevated lactic acidosis, and theweight of each compo-
nent should be studied and would likely require a large
multi-institutional network. With a larger study population,
cutoff levels for each laboratory measure would have been
based on statistical analysis instead of previously used
levels, and each component could have been weighted given
its relative associations with outcomes. Only neonates were
studied, so the results may not be applicable to other popu-
lations. The proposed composite outcome may not be a use-
ful marker in less complex populations. The composite
outcome was only compared with 4 other early outcome
measures, and the relationship to other early and late out-
comes warrants further investigation.432 The Journal of Thoracic and Cardiovascular SurgCONCLUSIONS
The ideal composite outcome in clinical research would
have a relatively high prevalence, be composed of clinically
meaningful components that are weighted appropriately,
and correlate with other short and long-term outcomes. A
composite outcome consisting of death, CPR, ECMO, ele-
vated lactate, and hepatic and renal injury is easily mea-
sured, reproducible, and highly associated with important
early operative outcomes in neonates undergoing cardiac
operations with CPB. The studied composite outcome had
a high prevalence rate, and its components were selected us-
ing prior evidence. This composite outcome could serve as
a useful end point for future clinical studies. Future studies
should further refine the studied composite outcome and de-
termine whether the composite outcome is associated with
long-term outcomes.
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